Details of the Drug Combinations

General Information of This Drug (ID: DMOWNB4)

Drug Name

2,3-dihydroxypropanal DMOWNB4

Synonyms

DL-Glyceraldehyde; glyceraldehyde; 2,3-Dihydroxypropanal; Glyceric aldehyde; Glycerose; Glycerinaldehyde; Glycerinformal; 56-82-6; Propanal, 2,3-dihydroxy-; 2,3-Dihydroxypropionaldehyde; DL-GLYC; Aldotriose; alpha,beta-dihydroxypropionaldehyde; 367-47-5; Glyceraldehyde, (+-)-; Propionaldehyde, 2,3-dihydroxy-; aldose; U 1188; D,L-glyceraldehyde; NSC 67934; BRN 0635844; AI3-24475; (+/-)-Glyceraldehyde; EINECS 206-695-9; EINECS 200-290-0; DLG; .alpha.,.beta.-Dihydroxypropionaldehyde; 2,3-dihydroxy-propionaldehyde; CHEBI:5445

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
2,3-dihydroxypropanal + Acetaminophen	DCX4E7O	Acetaminophen	Bacterial Meningitis	[2]
2,3-dihydroxypropanal + Empagliflozin	DCRUE77	Empagliflozin	Obesity, Visceral	[3]
------------------------------------------------------------------------------------

References

1	Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20764-9.
2	ClinicalTrials.gov (NCT00619203) Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis
3	ClinicalTrials.gov (NCT02833415) Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging